<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04866251</url>
  </required_header>
  <id_info>
    <org_study_id>Gag Reflex - 1</org_study_id>
    <nct_id>NCT04866251</nct_id>
  </id_info>
  <brief_title>Prevalence of Gag Reflex in Healthy Persons and Across Different Patient Groups and Its Relevance in Dysphagia Screening</brief_title>
  <official_title>Prevalence of Gag Reflex in Healthy Persons and Across Different Patient Groups and Its Relevance in Dysphagia Screening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Giessen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the prevalence of gag reflex in healthy young and healthy&#xD;
      older subjects as well as in acute stroke patients, in patients with Parkinsons´s Disease,&#xD;
      Myasthenia gravis, Multiple Sclerosis and in geriatric patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the clinical swallowing examination in acute stroke setting it is assumed that the absence&#xD;
      of gag reflex is a predictor of aspiration risk. According to Daniels et al. (1997)&#xD;
      aspiration can be predicted with 96% sensitivity in case of absent or abnormal gag reflex. In&#xD;
      clinical experience of investigators testing of gag reflex highly depends on&#xD;
      patients´compliance and individual anatomical features such as Mallampati score. Furthermore,&#xD;
      even if gag reflex is absent, swallowing does not have to be impaired.&#xD;
&#xD;
      The presence of gag reflex in healthy cohorts and dysphagic patients has been examined in a&#xD;
      few studies. Davies et al. (1995) have shown that in 37% of healthy volunteers gag reflex was&#xD;
      absent. Ramsey et al. (2005) have shown that approx. 89% of the patients without gag reflex&#xD;
      had dysphagia and 31% without dysphagia had a gag reflex. In both studies it was not stated&#xD;
      to what extent the gag reflex could be examined in case of a high Mallampati score.&#xD;
&#xD;
      The present study aims at assessing the prevalence of gag reflex in healthy and neurological&#xD;
      cohorts. The study protocol foresees testing of gag reflex in different oral areas (tongue,&#xD;
      velum, pharyngeal wall) and evaluating present reactions. The Mallampati score is assessed in&#xD;
      order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.&#xD;
&#xD;
      All patients are tested once by one examiner.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2016</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of gag reflex</measure>
    <time_frame>Baseline</time_frame>
    <description>Prevalence of gag reflex</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Neurological Diseases or Conditions</condition>
  <arm_group>
    <arm_group_label>Healthy young subject</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy older subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute stroke patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Parkinson´s Disease</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Multiple Sclerosis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Myasthenia gravis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Geriatric patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Gag reflex test; assessment of Mallampati Score</intervention_name>
    <description>Testing of gag reflex Assessment of Mallampati Score</description>
    <arm_group_label>Acute stroke patients</arm_group_label>
    <arm_group_label>Geriatric patients</arm_group_label>
    <arm_group_label>Healthy older subjects</arm_group_label>
    <arm_group_label>Healthy young subject</arm_group_label>
    <arm_group_label>Patients with Multiple Sclerosis</arm_group_label>
    <arm_group_label>Patients with Myasthenia gravis</arm_group_label>
    <arm_group_label>Patients with Parkinson´s Disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Healthy participants:&#xD;
&#xD;
             Neurological diseases Pre-diagnosed dysphagia Percutaneous endoscopic gastrostomy&#xD;
             (PEG) tube Head and neck tumours Chemo- and/or radiotherapy in the head and neck area&#xD;
             Reflux disease Chronic obstructive pulmonary disease (COPD) Previous surgeries on the&#xD;
             cervical spine or thyroid gland Vocal cord paresis&#xD;
&#xD;
          2. Geriatric patients Neurologic diseases&#xD;
&#xD;
          3. Stroke patients Head and neck tumours Chemo- and/or radiotherapy in the head and neck&#xD;
             area Reflux disease COPD Previous surgeries on the cervical spine or thyroid gland&#xD;
             Vocal cord paresis&#xD;
&#xD;
          4. Neurologic patients without stroke Head and neck tumours (except of intracranial&#xD;
             tumors= Chemo- and/or radiotherapy in the head and neck area Reflux disease COPD&#xD;
             Previous surgeries on the cervical spine or thyroid gland Vocal cord paresis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Braun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Giessen and Marburg, Campus Giessen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samra Hamzic, M.A.</last_name>
    <phone>+49 641 985 59233</phone>
    <email>samra.hamzic@neuro.med.uni-giessen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Giessen and Marburg</name>
      <address>
        <city>Gießen</city>
        <state>Hessen</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samra Hamzic, M.A.</last_name>
      <phone>+49 17699807230</phone>
      <email>samra.hamzic@neuro.med.uni-giessen.de</email>
    </contact>
    <investigator>
      <last_name>Samra Hamzic, M.A.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

